# Biomarkers of multi-organ dysfunction in ECMO: prognostic signposts for palliative transitions

## TL;DR

High lactate, liver issues, kidney failure, and inflammation are early signs that ECMO patients may not survive, helping doctors decide on palliative care.

## Contribution

The study identifies specific biomarker thresholds that strongly predict mortality in ECMO patients, aiding clinical decision-making.

## Key findings

- Lactate levels above 8 mmol/L at 12 hours or clearance below 22% indicate high mortality risk.
- Peak bilirubin over 15 mg/dL increases death risk fourfold and reflects poor liver function.
- Acute kidney injury requiring CRRT is linked to 60–80% mortality rates.

## Abstract

Consistently high lactate levels and poor clearance on ECMO are important early signs of poor perfusion and useless care. For example, lactate levels over 8 mmol/L at 12 h, staying above 2.5 mmol/L at 24 h, or clearance rates below 22% are all strong signs that a patient will die in the hospital. Beyond metabolic markers, signs of specific organ failure are grave prognostic factors. Total bilirubin is a better way to check for liver problems than enzymes. A peak bilirubin level of more than 15 mg/dL means that the liver is not clearing the bilirubin properly and increases the risk of death by four times. Acute kidney injury requiring renal replacement therapy (CRRT) reflects severe multi-organ failure and is independently associated with mortality rates of 60–80%. Systemic coagulopathy also marks clinical decline, with an overt DIC score ≥5 or a precipitous ≥50% drop in platelets on the first day carrying an 8–9-fold increased risk of death. Furthermore, a profound inflammatory response, evidenced by high interleukin-6 and procalcitonin levels (≥0.5 μg/L), correlates with refractory shock and significantly worse outcomes compared to nonspecific markers like CRP. Ultimately, the persistence of these metabolic, hepatic, renal, and inflammatory abnormalities suggests irreversible organ damage and a poor prognosis.